HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
暂无分享,去创建一个
Y. Andreeva | V. Strelnikov | S. Khokhlova | T. Kekeeva | A. Kalinkin | A. Tanas | V. Dmitriev | A. Tyulyandina | V. Nechushkina | S. Kutsev | M. Volkonsky | Tatiana Tikhomirova | Anatoly Popov | Maria Kuzmenko | N. Chernorubashkina | Valeria Saevets | Olga Vedrova | Sergei Andreev | T. Tikhomirova | V. Saevets | O. Vedrova | S. Andreev
[1] L. Pecciarini,et al. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! , 2022, Cancers.
[2] Xiaoxiang Chen,et al. Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability , 2022, BJOG : an international journal of obstetrics and gynaecology.
[3] A. Rappa,et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay , 2022, Pathologica.
[4] Negesse Mekonnen,et al. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors , 2022, Frontiers in Oncology.
[5] S. Fröhling,et al. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) , 2022, npj Precision Oncology.
[6] Bonnie V. Dougherty,et al. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort , 2022, BMC Cancer.
[7] W. Weichert,et al. 216 An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer , 2021, Late breaking abstracts.
[8] P. Roepman,et al. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types , 2021, Clinical Cancer Research.
[9] Svetlana N. Kazakova,et al. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia , 2021, Breast Cancer Research and Treatment.
[10] Natalie Y L Ngoi,et al. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? , 2021, ESMO open.
[11] A. Sood,et al. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer , 2021, Cancers.
[12] A. Sood,et al. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy , 2021, Cancers.
[13] F. Marmé,et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.
[14] B. Monk,et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.
[15] M. Morgan,et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.
[16] E. Imyanitov,et al. Abstract 1241: Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study , 2018, Epidemiology.
[17] K. Lisowska,et al. Advances in ovarian cancer therapy , 2017, Cancer Chemotherapy and Pharmacology.
[18] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[19] E. Birney,et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.
[20] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[21] S. Cooper,et al. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma , 2016, Molecular Cancer Research.
[22] Stefan M Willems,et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate , 2014, Modern Pathology.
[23] M. Biffoni,et al. A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells , 2012, PloS one.
[24] A. Knudson,et al. Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.